Shanghai Shyndec Pharmaceutical (600420.SH) subsidiary obtains the drug registration certificate for Bisoprolol Amlodipine tablets.
GuoYao Modern (600420.SH) announced that its wholly-owned subsidiary, GuoYao Group Rongsheng Pharmaceutical Co., Ltd. (referred to as GuoYao Rongsheng), has received the Drug Registration Certificate for Bisoprolol Amlodipine Tablets issued by the National Medical Products Administration. Bisoprolol Amlodipine Tablets are an alternative therapy for the treatment of hypertension and are suitable for patients who are currently taking a single drug at the same dosage as the compound preparation and have good blood pressure control.
Shanghai Shyndec Pharmaceutical (600420.SH) announced that its wholly-owned subsidiary, China National Pharmaceutical Group Rongsheng Pharmaceutical Co., Ltd. (referred to as Rongsheng), has received the Drug Registration Certificate for Bisoprolol Amlodipine Tablets issued by the National Medical Products Administration. Bisoprolol Amlodipine Tablets, as an alternative therapy for hypertension, are suitable for patients who are currently taking the same dose of a single drug and have good blood pressure control while on compound preparations.
Related Articles
SINOHEALTH TECH (02361) expects to increase the public shareholding ratio by no less than 8 percentage points by the end of June 2027.
PRU (02378) spent 17.1389 million to buy back 1.6682 million shares on August 5.
BEKE-W (02423) repurchased 531,900 shares for $3 million on August 5.
SINOHEALTH TECH (02361) expects to increase the public shareholding ratio by no less than 8 percentage points by the end of June 2027.
PRU (02378) spent 17.1389 million to buy back 1.6682 million shares on August 5.
BEKE-W (02423) repurchased 531,900 shares for $3 million on August 5.
RECOMMEND
